Health Economics›Classical Hodgkin lymphoma›Untreated early-stage unfavorable (ESU)

Untreated early-stage unfavorable (ESU)

Classical Hodgkin lymphoma · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
A-AVD Variant #01	—	R 116 574	28d	—	—	—	—	2
RABVD Variant #01	—	R 73 691	28d	—	—	—	—	—
eBEACOPP-ABVD Variant #01 Partial	—	R 5 873	28d	—	—	—	—	—
ABVD Variant #01	—	R 2 916	28d	—	—	—	—	4
Stanford V Variant #05 Partial	—	R 2 608	28d	—	—	—	—	1
EBVP Variant #01	—	R 1 831	21d	—	—	—	—	—
BEACOPP Variant #01 Partial	—	R 1 672	21d	—	—	—	—	—
MOPP-ABV Variant #01 Partial	—	R 862	28d	—	—	—	—	—

8 of 8 regimens shown